Bavarian Nordic ASCHIX:BAVAC 84 Return-on-Tangible-Equity is 0.99% as of Mar. 2026, which is 81% below its 10-year median of 5.08. GuruFocus rates CHIX:BAVAC with a GF Score™ of 84/100 and a GF Value™ of kr161.93 (Modestly Overvalued). The stock has 3 warning signs investors should review. Among 1,199 Biotechnology companies, Bavarian Nordic AS ranks better than 90.58% on this metric.
Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. Bavarian Nordic AS's annualized net income for the quarter that ended in Mar. 2026 was kr68 Mil. Bavarian Nordic AS's average shareholder tangible equity for the quarter that ended in Mar. 2026 was kr6,861 Mil. Therefore, Bavarian Nordic AS's annualized Return-on-Tangible-Equity for the quarter that ended in Mar. 2026 was 0.99%.
The historical rank and industry rank for Bavarian Nordic AS's Return-on-Tangible-Equity or its related term are showing as below:
CHIX:BAVAc'
s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: -79.16 Med: 5.08 Max: 58.24
Current: 18.28
During the past 13 years, Bavarian Nordic AS's highest Return-on-Tangible-Equity was 58.24%. The lowest was -79.16%. And the median was 5.08%.
CHIX:BAVAc's Return-on-Tangible-Equity is ranked better than 90.58% of 1199
companies
in the Biotechnology industry
Industry Median: -42.4
vs CHIX:BAVAc: 18.28
Bavarian Nordic AS (CHIX:BAVAc) Return-on-Tangible-Equity Explanation
Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.
Be Aware
Net Income is used.
Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.
Bavarian Nordic AS Return-on-Tangible-Equity Related Terms
Bavarian Nordic AS Return-on-Tangible-Equity Historical Data
* Premium members only.
The historical data trend for Bavarian Nordic AS's Return-on-Tangible-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Bavarian Nordic AS Return-on-Tangible-Equity Chart
CHIX:BAVAC vs VRTX, REGN, ALNY: Return-on-Tangible-Equity Comparison
For the Biotechnology subindustry, Bavarian Nordic AS's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Bavarian Nordic AS Return-on-Tangible-Equity vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Bavarian Nordic AS's Return-on-Tangible-Equity distribution charts can be found below:
* The bar in red indicates where Bavarian Nordic AS's Return-on-Tangible-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is four times the quarterly (Mar. 2026) net income data.
Return-on-Tangible-Equity is displayed in the 10-year financial page.
What does a Return-on-Tangible-Equity of 0.99% mean?
Bavarian Nordic AS (CHIX:BAVAC) has a Return-on-Tangible-Equity of 0.99% as of Mar. 2026. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Bavarian Nordic AS and its competitors. This is 81% below median its historical median of 5.08. According to the industry distribution chart, Bavarian Nordic AS ranks #113 out of 1199 companies in the Biotechnology industry, placing it in the top 9.4%.
Is Bavarian Nordic AS's Return-on-Tangible-Equity too high?
Bavarian Nordic AS's current Return-on-Tangible-Equity of 0.99% is 81% below median its 10-year median of 5.08. Based on the distribution chart, Bavarian Nordic AS ranks #113 out of 1199 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Bavarian Nordic AS has a GF Score™ of 84/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Bavarian Nordic AS's Return-on-Tangible-Equity compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Bavarian Nordic AS ranks #113 out of 1199 companies for Return-on-Tangible-Equity. This places Bavarian Nordic AS in the top 9% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Equity for a Biotechnology company?
A good Return-on-Tangible-Equity depends on the Biotechnology industry context. However, Return-on-Tangible-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Equity mean?
A high Return-on-Tangible-Equity can signal that a stock is expensive relative to its fundamentals. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Bavarian Nordic AS and its competitors. Bavarian Nordic AS's current Return-on-Tangible-Equity is 0.99%, which is 81% below median its own 10-year median of 5.08. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bavarian Nordic AS stock overvalued right now?
Based on GuruFocus' analysis, Bavarian Nordic AS (CHIX:BAVAC) is currently considered Modestly Overvalued. The stock's GF Value™ is kr161.93, compared to a current price of kr188.30 — trading 16.3% above its estimated fair value. The current Return-on-Tangible-Equity is 0.99%, which is 81% below median its 10-year median of 5.08. Bavarian Nordic AS's overall GF Score™ is 84/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Equity calculated?
Return-on-Tangible-Equity is calculated from a company's financial statements. For Bavarian Nordic AS (CHIX:BAVAC), the current Return-on-Tangible-Equity is 0.99% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Bavarian Nordic AS (CHIX:BAVAC) Overvalued in 2026?
Based on GuruFocus' analysis, Bavarian Nordic AS stock appears to be overvalued.
The current stock price of kr188.30 is trading 16.3% above its estimated GF Value™ of kr161.93.
GuruFocus considers Bavarian Nordic AS to be Modestly Overvalued.
Key valuation signals for CHIX:BAVAC:
Return-on-Tangible-Equity: 0.99% (81% below median its 10-year median of 5.08)
GF Value™: kr161.93 vs. price of kr188.30 (16.3% above fair value)
No single metric tells the full story. See the CHIX:BAVAC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Bavarian Nordic AS is a biotechnology company focused on the research, development, manufacturing, and commercialization of life-saving vaccines. The group is a supplier of mpox and smallpox vaccines to governments to enhance public health preparedness and has a portfolio of travel vaccines. The vast majority of the company's revenue is generated in the United States, Germany, and other geographic markets. Its products include Encepur, Jynneos, Rabipur, Vaxchora, VIMKUNYA and Vivotif.
84GF Score
Get the complete analysis for CHIX:BAVAC
Return-on-Tangible-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CHIX:BAVAC has been successfully added to your 
